Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiationSAN FRANCISCO and BERLIN, ...
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...
A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance ...
According to MarketsandMarkets™, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 ...
Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help ...
A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...
After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for ...
Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...
According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an ...
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare subtype of non-Hodgkin lymphoma that frequently presents with multiorgan involvement. We report a diagnostically challenging ...
As interest in CAR T cells and immune-based oncology therapies increases, efficient phenotyping of cell therapy products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results